Ryan J. Watts - 03 Jan 2026 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Reporting relationship: President and CEO, Director
Issuer ticker: DNLI
Reported as of: 03 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jan 2026, 18:48:48 UTC
Prior SEC filing: 05 Sep 2025
Next SEC filing: 08 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Tyler Nielsen, by power of attorney

Key filing fact

Ryan J. Watts filed Form 4 for Denali Therapeutics Inc. (DNLI) on 05 Jan 2026.

Key facts

This page summarizes Ryan J. Watts's Form 4 filing for Denali Therapeutics Inc. (DNLI).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 Jan 2026, 18:48.

Change

Previous filing in this sequence was filed on 05 Sep 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001724310 Primary reporting owner

Watts Ryan J.

Relationship: President and CEO, Director
Address: C/O DENALI THERAPEUTICS INC., 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Signature: /s/ Tyler Nielsen, by power of attorney
Signature date: 05 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DNLI transaction

Common Stock

Award

Transaction value: $0
Shares: +78,960
Change %: +31%
Price: $0.000000
Shares after: 332,031
Date: 03 Jan 2026
Ownership: Direct
Footnotes: F1, F2

DNLI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 2,152,604
Date: 03 Jan 2026
Ownership: See footnote
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DNLI transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +236,880
Change %
Price: $0.000000
Shares after: 236,880
Date: 03 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 236,880
Exercise price: $16.27
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on January 3, 2027 (the "Vesting Commencement Date") and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date.

Footnote F2

Includes 184,915 Unvested RSUs.

Footnote F3

The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.

Footnote F4

25% of the shares subject to the option shall vest on January 3, 2027, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date